Boston Scientific Co. (NYSE:BSX) Shares Bought by Groupama Asset Managment

Groupama Asset Managment boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 10.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 952,044 shares of the medical equipment provider's stock after acquiring an additional 88,081 shares during the period. Groupama Asset Managment owned 0.06% of Boston Scientific worth $80,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Triad Wealth Partners LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Values First Advisors Inc. purchased a new position in shares of Boston Scientific in the third quarter worth $28,000. Dunhill Financial LLC lifted its holdings in shares of Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 152 shares in the last quarter. Andra AP fonden purchased a new stake in shares of Boston Scientific during the second quarter valued at $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new stake in Boston Scientific in the 3rd quarter worth about $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Up 1.7 %

BSX traded up $1.51 during trading hours on Tuesday, reaching $90.23. 4,610,782 shares of the company's stock traded hands, compared to its average volume of 6,002,105. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $87.50 and a 200 day moving average price of $81.44. Boston Scientific Co. has a 52-week low of $54.86 and a 52-week high of $91.93. The firm has a market capitalization of $132.98 billion, a PE ratio of 74.55, a PEG ratio of 2.65 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to analysts' expectations of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm's quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.50 EPS. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the transaction, the executive vice president now owns 34,748 shares of the company's stock, valued at $2,913,967.28. This trade represents a 16.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. The trade was a 9.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 328,157 shares of company stock worth $27,957,676. 0.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Citigroup raised their price target on shares of Boston Scientific from $92.00 to $98.00 and gave the company a "buy" rating in a report on Thursday, October 24th. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Stifel Nicolaus raised their price target on Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, October 18th. BTIG Research upped their price objective on Boston Scientific from $84.00 to $93.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Finally, Bank of America raised their target price on Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $93.52.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.